Chipotle reports lower profit in Q2 2025
The Q2 results revealed a mixed performance with increased total revenue but decreased comparable restaurant sales and operating margins.
The company's total revenue saw a 3% rise to $3.1bn, driven by new restaurant openings, yet comparable restaurant sales fell 4%.
Operating margin decreased to 18.2% from 19.7% and restaurant-level operating margin declined to 27.4% from 28.9%.
Despite the downturn in some areas, Chipotle continued its expansion by opening 61 new company-owned restaurants, with 47 featuring the Chipotlane drive-through facility.
Digital sales accounted for 35.5% of total food and beverage revenue.
Adjusted net income also saw a marginal decline to $450.4m, or $0.33 per adjusted diluted share, compared to $463.0m, or $0.34 per adjusted diluted share, in Q2 2024.
The brand's stock repurchase programme remained active, with $435.9m worth of stock bought back at an average price of $50.16 per share.
As of the end of the quarter, Chipotle had $838.8m available for further repurchases, bolstered by an additional $400m authorised by the board on 10 June 2025.
Cost efficiencies in food, beverage and packaging, which fell to 28.9% of total revenue, were offset by inflation in ingredient costs, particularly for steak and chicken.
Labour expenses rose to 24.7% of total revenue, attributed to lower sales volumes despite the benefits of previous menu price increases and efficient labour management.
General and administrative expenses decreased to $172.2m, largely due to reduced performance bonuses and stock-based compensation.
On a non-generally accepted accounting principles (GAAP) basis, general and administrative expenses for Q2 2025 were $159.9m, against $171.3m in the previous quarter.
The effective income tax rate also saw a slight reduction to 24.5%, driven by lower non-deductible expenses.
Looking ahead to the full year 2025, management expects comparable restaurant sales to remain flat and plans to open between 315 and 345 new company-owned restaurants, with more than 80% featuring a Chipotlane.
The anticipated underlying effective full-year tax rate is estimated to be between 25% and 27% before discrete items.
For Q1 (ended 31 March 2025), Chipotle reported a 6.4% increase in revenue to $2.9bn, compared with $2.7bn posted in the same period of the previous year.
"Chipotle reports lower profit in Q2 2025" was originally created and published by Verdict Food Service, a GlobalData owned brand.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Blackstone says real estate executive Wesley LePatner was among those killed in NYC shooting
The Blackstone executive Wesley LePatner was among those killed on Monday by a gunman who entered the company's Park Avenue offices, the private equity giant said in a statement Tuesday morning. LePatner, a mother and wife, was the $1.2 trillion firm's global head of core+ real estate and CEO of Blackstone Real Estate Income Trust, an evergreen real estate fund. Her death has left staff at the New York-based asset manager "heartbroken," the statement said. "Words cannot express the devastation we feel. Wesley was a beloved member of the Blackstone family and will be sorely missed. She was brilliant, passionate, warm, generous, and deeply respected within our firm and beyond. She embodied the best of Blackstone," the statement continued. LePatner, a Yale graduate and trustee of New York's Met Museum, was an executive at Goldman Sachs before joining Blackstone in 2014. She told Business Insider in 2022 that her unit was, "for all intents and purposes, a startup." "I faced all the challenges one could imagine when building a multibillion-dollar business — from hiring to ensuring standards remain high, moving quickly to keep up with growth, and staying ahead of market swings and growing pains," she said. She also served on the board for the UJA-Federation of New York, which honored her at its Wall Street dinner in 2023. Blackstone's President Jon Gray presented her with a leadership award and lauded her ascent in finance and her support of women on Wall Street, according to a press release. LePatner is one of four victims who lost their lives to the gunman, who has been identified by the police as Shane Tamura. The gunman died of an apparent self-inflicted gunshot wound in the building.
Yahoo
3 hours ago
- Yahoo
Potential Multi-Year Growth for Saia (SAIA) If Freight Industry Rebounds
The London Company, an investment management company, released 'The London Company SMID Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. Following a downturn in Q1, U.S. stocks experienced a double-digit gain in Q2, amid volatility stemming from tariff news. A risk-on rally followed due to a temporary pause in tariff escalations, widespread optimism around enterprise AI, and a healthy earnings outlook. Against this backdrop, the portfolio fell 0.6% (-0.8% net) during the second quarter vs. an 8.6% increase in the Russell 2500 Index. Sector allocation contributed to the fund's performance in the quarter, while stock selection detracted. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company SMID Cap Strategy highlighted stocks such as Saia, Inc. (NASDAQ:SAIA). Saia, Inc. (NASDAQ:SAIA) is a North America-based transportation company. The one-month return of Saia, Inc. (NASDAQ:SAIA) was 9.19%, and its shares lost 23.58% of their value over the last 52 weeks. On July 28, 2025, Saia, Inc. (NASDAQ:SAIA) stock closed at $323.23 per share, with a market capitalization of $8.61 billion. The London Company SMID Cap Strategy stated the following regarding Saia, Inc. (NASDAQ:SAIA) in its second quarter 2025 investor letter: "Saia, Inc. (NASDAQ:SAIA) – SAIA remained weak this quarter as the lingering 'freight recession' drags on for almost its third year. We remain convicted in our ownership of SAIA due to its solid balance sheet and strong network growth plan. We believe the company could be a multi-year compounder, assuming the freight industry returns to normal demand patterns. A long line of trucks transporting goods across the open road, symbolizing the long-distance transportation services of the company. Saia, Inc. (NASDAQ:SAIA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Saia, Inc. (NASDAQ:SAIA) at the end of the first quarter, compared to 31 in the previous quarter. In the second quarter of 2025, Saia, Inc. (NASDAQ:SAIA) announced revenue of $817 million, marking a 0.7% decrease compared to the same quarter last year. While we acknowledge the potential of Saia, Inc. (NASDAQ:SAIA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Saia, Inc. (NASDAQ:SAIA) and shared Polen US SMID Company Growth Strategy's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
3 hours ago
- Business Wire
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA ®, acquired by Johnson & Johnson for $14.6 billion in April 2025. Dr. Mates said: "Medincell is entering a new era and I'm excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innovation and delivering meaningful solutions for patients." Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies. Dr. Kunsch said: 'Throughout my career, I've seen how innovation and collaboration can transform bold ideas into meaningful impact. These values are deeply rooted at Medincell. They've already taken the company far and laid a strong foundation for a new phase of growth. I'm excited to contribute my experience to support the executive team and fellow board members in driving the company's continued success.' These nominations aim to further strengthen the expertise of Medincell's Board of Directors, which currently includes: Philippe Guy (Chairman) - Former Head of BCG's Global Health Care Practice and member of BCG's Worldwide Executive Committee Christophe Douat - CEO of Medincell Elisabeth Kogan - CEO of Clexio Bioscience, former SVP at Teva where she led global generic and specialty R&D Tone Kvåle - CFO of Herantis Pharma, with over 25 years of biotech finance leadership Virginie Lleu - Senior Partner at WittKieffer, with over 30 years of experience in executive search for the pharmaceutical industry Pascal Touchon - Former Global Head of Cell & Gene Therapy at Novartis Oncology, CEO then Chairman of Atara Biotherapeutics, Inc. Philippe Guy, Chairman of the Board of Medincell, said: 'The Board has made it a priority to strengthen its collective expertise in preparation for the future. The addition of Dr. Mates and Dr. Kunsch brings a wealth of experience in innovation, strategic vision, and influential networks. Their contributions will play a key role in reinforcing our leadership, expanding our impact, and creating lasting value.' Christophe Douat, CEO and Director of Medincell, said: 'The coming years will be the most transformative in Medincell's history. Sharon and Charles will bring invaluable experience and world-class expertise in science and innovation to our Board, as Medincell remains deeply committed to improving patients' lives.' The appointments of Dr. Mates and Dr. Kunsch, along with that of Pascal Touchon - who was previously appointed by Medincell's Board of Directors (see press release) - is subject to shareholder approval at the General Assembly to be held on September 11, 2025. About Dr. Mates Sharon Mates, Ph.D., co-founded Intra-Cellular Therapies in 2002 with Nobel Laureate Dr. Paul Greengard, building the company on his groundbreaking research into intracellular signaling to pioneer treatments for psychiatric and neurologic disorders. As Co-founder, Chairman and CEO, Dr. Mates led the development of CAPLYTA ® (lumateperone), a breakthrough therapy for schizophrenia and bipolar depression, with analysts projecting peak annual sales of up to $5 billion. Under her leadership, the company went public and grew to a market capitalization of over $10 billion before its acquisition by Johnson & Johnson for $14.6 billion in April 2025. Previously, for almost a decade, Dr. Mates served as President of North American Vaccine Inc., where she oversaw the development of pediatric vaccines. She holds a Ph.D. in anatomy and neuroscience and completed her postdoctoral training at Harvard Medical School and Massachusetts General Hospital. In addition to her scientific leadership as a research analyst and investment banker in the life sciences sector, she has co-founded several biotech companies and has sat on several non-profit boards. Dr. Mates was named to Forbes' '50 Over 50 – Innovation' list in recognition of her lasting impact on neuroscience and biotech innovation. About Dr. Kunsch Charles Kunsch, Ph.D., is a seasoned life sciences executive and investor with over 30 years of leadership in R&D, venture capital, and biotech innovation. He served as Managing Director at AbbVie Ventures, where he led investments in manyhigh-impact biotech companies including Prevail Therapeutics (acquired by Lilly) and Tidal Therapeutics (acquired by Sanofi) among others. Earlier in his career, he held senior scientific roles at AbbVie, AtheroGenics and Human Genome Sciences. Kunsch holds a Ph.D. in Immunology from Pennsylvania State University College of Medicine and completed postdoctoral training at the Roche Institute of Molecular Biology. He currently serves as a Venture Partner at Dreavent Capital, Vice Chair of the Board at Massachusetts Biomedical Initiatives, Board of Trustees of the Penn State Research Foundation, and is a board member at Captor Therapeutics, Antiverse and NextRNA. About Medincell Medincell is a clinical and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities. These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements. A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements. This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.
